Lilly files lasmiditan for migraine
Eli Lilly has filed an application in the US to market lasmiditan for the acute treatment of migraine with or without aura in adults.
Read More
Tag: SPARTAN
Lilly’s novel migraine drug hits PhIII targets
Eli Lilly’s investigational, oral, first-in-class molecule lasmiditan has hit key targets a late-stage trial assessing its safety and efficacy as a treatment for acute migraine, raising hopes for a new approach to managing the condition.
Read More
- CERo reports encouraging early data from phase 1 trial of CER‑1236
- ENA Respiratory begins dosing in phase 2 study of INNA‑051 nasal spray
- Argo Biopharma doses first patient in phase 2b trial of BW‑20829
- Akari files new patent and advances second ADC targeting CEACAM5
- BioMed X launches kidney disease project in partnership with the government of Barbados
